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ABSTRACT
Basophils represent less than 1% of peripheral blood leukocytes. They are often recruited to the site of allergic
inflammation, albeit in small numbers. However, it remained uncertain whether basophils play any significant
role in allergic reactions or act as minor and redundant ‘circulating mast cells’. We have recently demonstrated
that basophils play critical roles in systemic anaphylaxis and chronic allergic inflammation, distinctively from
mast cells. Basophils are one of the major players in the IgG- but not IgE-mediated systemic anaphylaxis, in
contrast to mast cells. In response to the allergen-IgG immune complexes, basophils release the platelet-
activating factor rather than histamine as the major chemical mediator to induce the systemic anaphylaxis. The
depletion of basophils protects mice from death due to anaphylactic shock. Basophils also play a crucial role in
the development of the IgE-mediated chronic allergic inflammation with massive eosinophil infiltration in the
skin, independently of T cells and mast cells, even though basophils account for only ～2% of the infiltrates.
The basophil depletion shows a therapeutic effect on on-going allergic inflammation. Accumulating evidence
suggests that basophils function as initiators rather than effectors of the chronic allergic inflammation. Thus, ba-
sophils and their products seem to be promising therapeutic targets for allergic disorders.
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INTRODUCTION
Circulating basophils share several features with
tissue-resident mast cells, including the presence of
basophilic granules in the cytoplasm, the surface ex-
pression of high-affinity IgE receptor FcεRI, and the
release of chemical mediators such as histamine
upon stimulation.1,2 Because of these similarities and
their small numbers, basophils have often been ne-
glected or considered as minor and possibly redun-
dant ‘circulating mast cells’.3 Moreover, mice, a use-
ful laboratory animal species, were erroneously
thought to lack basophils for a long time, because
mouse basophils have far fewer basophilic granules
stained with conventional methods such as Giemsa
stain, as compared with human basophils.4,5 The dis-
covery that basophils rapidly secrete large quantities
of Th2 cytokines such as IL-4 in both humans and
mice3,6-10 has changed the traditional image of baso-
phils that they release only preformed histamine and
newly synthesized leukotriene C4 after stimulation.
This has also provided insight into a possible role for
basophils in allergic diseases and immunity to patho-
gens such as parasites. Nevertheless, the functional
studies of basophils have long been hampered by the
lack of suitable animal models, including mice defi-
cient only in basophils.
Recent studies have solved this bottleneck by us-
ing the adoptive transfer of basophils from normal to
FcεRI-deficient mice or establishing basophil-
depleting antibodies.11-15 These studies have defined
previously-unrecognized roles for basophils, and have
markedly changed our view of basophils from a ne-
glected minority to key players in immune regulation
and allergic responses. Basophils have been shown to
drive the differentiation of T cells in lymph nodes
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Fig. 1 Classical and alternative pathways toward systemic anaphylaxis. 
The classical pathway utilizes mast cels, IgE, and histamine while the alter
native pathway utilizes basophils and/or macrophages, IgG, and PAF.
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from naïve to Th2-type cells through the secretion of
IL-4 and thymic stormal lymphopoietin (TSLP) in re-
sponse to protease allergens such as papain.13 Baso-
phils also play an important role in the augmentation
of humoral memory responses in that upon the re-
exposure to the antigen basophils secrete IL-4 and IL-
6 which in turn stimulate memory B cells and T cells
for their proliferation and antibody production.14 In
this review, we focus on the newly-defined roles for
basophils in allergic responses, including IgG-
mediated systemic anaphylaxis and IgE-mediated
chronic allergic inflammation in mice,11,12,15 and dis-
cuss the possible involvement of basophils in human
allergic disorders.
THE ROLE FOR BASOPHILS IN SYSTEMIC
ANAPHYLAXIS
Anaphylaxis is an acute-onset, potentially fatal sys-
temic allergic reaction.16,17 The term anaphylaxis was
created by Dr. Charles Robert Richet, the French
physiologist, who received the Nobel Prize in Physi-
ology or Medicine in 1913.18 He and his colleague
Paul Portier reported in 1902 the unexpected experi-
mental result using dogs that were immunized with
venom from sea anemones. They intended to make
dogs tolerant to the venom by injecting them with
non-lethal dose of venom. Shibasaburo Kitasato and
Emil von Behring had already demonstrated that ani-
mals immunized with bacterial toxins produced anti-
toxin, which we now know as neutralizing antibodies.
In contrast to the original intention of Richet and
Portier, the immunized dogs displayed fatal reactions
to the second injection of the venom even in a small
dose. To describe this curious phenomenon, they cre-
ated the novel word, anaphylaxis, that was derived
from the Greek words a- (against) and -phylaxis (pro-
tection).
IgE- VERSUS IgG-MEDIATED SYSTEMIC ANA-
PHYLAXIS
Anaphylaxis is commonly triggered by exposure to
allergens including foods, insect venoms, and medi-
cations through immunological mechanisms, al-
though non-immunological reactions such as those
triggered by exercise and cold are involved in some
cases.16,17 It is well documented that IgE and mast
cells play pivotal roles in the induction of anaphylaxis
(Fig.1 top).19 When IgE antibodies against a given al-
lergen are produced by B cells in individuals sensi-
tized with the allergen, they circulate in the periph-
eral blood and bind to FcεRI expressed on the sur-
face of tissue-resident mast cells. The re-exposure to
the same allergen triggers the mast cell activation
through cross-linking of IgE-Fcε RI complexes by the
allergen, leading to the release of chemical media-
tors, such as histamine, that are pre-formed and
stored in secretory granules of mast cells.19-21 The
chemical mediators act on many types of cells in the
body, including vascular endothelial cells and bron-
chial smooth muscle, and induce anaphylactic mani-
festations such as hypotension and dyspnea.22
It is not essential to distinguish the molecular
mechanisms underlying different types of systemic
anaphylaxis with regard to clinical diagnosis and
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Fig. 2 Basophils are one of the major players in the IgG-
mediated systemic anaphylaxis. When alergens enter the 
blood stream, they form immune complexes with specific 
IgG antibodies that circulate in the blood. Circulating baso-
phils eficiently capture the immune complexes through their 
receptors for IgG (IgG-R), and are activated to release PAF, 
that in turn stimulates vascular endothelial cels, resulting in 
the increased vascular permeability leading to hypotension.
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acute treatment.17 The prompt intramuscular injec-
tion of epinephrine is needed to treat the anaphylactic
shock regardless of the underlying mechanism. How-
ever, it is very important to understand the molecular
basis of anaphylaxis for the development of risk re-
duction strategies and the prevention of recurrence.17
There are few prospective studies of induced anaphy-
laxis in human subjects because of the potentially
rapid, life-threatening outcome. Therefore, many ef-
forts have been made to develop and analyze the
modes of anaphylaxis in laboratory animals, particu-
larly mice. Such studies indicated that the classical
pathway utilizing IgE and mast cells does not account
for all anaphylactic responses. Mice deficient for mast
cells, IgE or FcεRIα chain could develop active sys-
temic anaphylaxis whereas FcRγ−− mice that lack the
expression of FcεRI and stimulatory IgG receptors
displayed no apparent sign of active systemic anaphy-
laxis.23-27 These results suggested that not only IgE
but also IgG played a critical role in the induction of
systemic anaphylaxis. Indeed, mice that were pas-
sively sensitized with allergen-specific monoclonal
IgG, particularly IgG1 subclass, developed systemic
anaphylaxis upon exposure to the corresponding al-
lergen.25,26 When the mice were pre-treated with anti-
FcγRIIIII mAb, the IgG-mediated systemic anaphy-
laxis was inhibited,27 indicating the involvement of
the low affinity IgG receptor FcγRIII. These results
implied that in addition to the classical pathway of
anaphylaxis, an alternative pathway is operative in
mice, in which non-mast cells, IgG, and FcγRIII are
involved in place of mast cells, IgE, and FcεRI.28
BASOPHIL IS ONE OF THE MAJOR PLAYERS IN
THE IgG- BUT NOT IgE-MEDIATED SYSTEMIC
ANAPHYLAXIS
In order to identify cells responsible for the IgG-
mediated systemic anaphylaxis, we first screened
candidate cells by examining their ability to capture
the allergen-IgG immune complexes in the mouse
model of penicillin allergy.15 Mice were passively sen-
sitized with intravenous injection of penicillin V
(PenV)-specific monoclonal IgG1, and subsequently
challenged with intravenous injection of PenV-
conjugated bovine serum albumin (PenV-BSA) as the
allergen. This induced typical signs of systemic ana-
phylaxis, including the drastic drop (－6℃) in the
body temperature within 30 min after the challenge,
in both mast cell-sufficient and deficient mice. Flow
cytometric analysis of cells isolated from mice imme-
diately after the allergen challenge revealed that vari-
ous types of cells captured the allergen-IgG immune
complexes on the cell surfaces, including NK cells,
macrophages, monocytes, dendritic cells, neutro-
phils, eosinophils, basophils and mast cells. Among
them, basophils bound the greatest amount of the al-
lergen per cell (Fig.2), and the binding was strongly
inhibited when the mice were treated with anti-
FcRIIIII mAb before the sensitization with IgG1.15
Thus, basophils were thought to be a good candidate
of the cell responsible for IgG-mediated systemic ana-
phylaxis. No study has explored the possible involve-
ment of basophils in the IgG-mediated systemic ana-
phylaxis, most likely due to the lack of analytical tools
such as mice deficient for only basophils
We have recently developed a mAb Ba103 specific
to mouse CD200R3, a CD200 receptor-like glycopro-
tein,12,29 and found that Ba103 selectively depletes ba-
sophils when administered in vivo.12 Thus, we have
succeeded in establishing mice that are transiently
deficient for only basophils. The basophil depletion
with Ba103 efficiently ameliorated the PenV-specific,
IgG1-mediated systemic anaphylaxis.15 In contrast,
the depletion of macrophages, NK cells, neutrophils,
or eosinophils showed no significant effect on the
anaphylaxis under our experimental conditions. Of
note, the IgE-mediated systemic anaphylaxis was not
significantly affected by the basophil depletion, in ac-
cord with the fact that mast cell-deficient mice cannot
develop the IgE-mediated anaphylaxis. These results
demonstrated that basophil is a major player in IgG-
mediated systemic anaphylaxis but not IgE-mediated
one (Fig.1 middle row and Fig.2).
We next examined the contribution of basophils to
anaphylaxis under conditions closer to the real life,
that is, active systemic anaphylaxis, in that mice were
immunized with PenV-conjugated ovalbumin (PenV-
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OVA) and 14 days later challenged with intravenous
injection of PenV-BSA. This protocol induced severe
anaphylaxis, and all mice analyzed, including mast
cell-deficient mice, died from anaphylactic shock. The
basophil depletion with Ba103 before the allergen
challenge protected mast cell-deficient mice, but not
wild-type mice, from anaphylactic death.15 These re-
sults demonstrated that both basophils and mast cells
make the critical contribution to active systemic ana-
phylaxis, most likely through distinct mechanisms:
IgG-mediated one utilized by basophils and IgE-
mediated one by mast cells.
BASOPHILS RELEASE PAF RATHER THAN HIS-
TAMINE TO INDUCE IgG-MEDIATED ANAPHY-
LAXIS
Anti-histamine showed little or no inhibitory effect on
the IgG1-mediated passive anaphylaxis even though
it efficiently ameliorated the IgE-mediated one. In
contrast, antagonists of platelet-activating factor
(PAF) almost completely inhibited the IgG1-mediated
anaphylaxis, indicating that PAF rather than hista-
mine is the major chemical mediator in the IgG1-
mediated anaphylaxis,15 unlike in the IgE-mediated
one. Basophils released much higher amounts of
PAF as compared to other types of cells when stimu-
lated with the allergen-IgG immune complexes. The
intravenous injection of PAF or histamine alone in-
duced the drastic drop in the body temperature as ob-
served in the IgG1-mediated anaphylaxis. However,
the amounts necessary for inducing the same extent
(－5℃) of drop in the body temperature differed be-
tween two reagents: 3 mg of histamine was needed
while as little as 100 ng of PAF was sufficient. Based
on the in vitro measurement, 100 ng of PAF can be
released from 3 × 105 basophils, which is close to the
total number of basophils in peripheral blood, spleen
and bone marrow. Thus, basophils can elicit system
anaphylaxis through the release of PAF that has
30,000-times higher potency than histamine (Fig.1
middle row and Fig.2), even though basophils ac-
count for less than 1% of leukocytes in the body.
MACROPHAGE IS ANOTHER MAJOR PLAYER
IN THE IgG-MEDIATED SYSTEMIC ANAPHY-
LAXIS
Finkelman and his colleagues previously reported
that macrophages played a critical role in the distinct
model of active systemic anaphylaxis.27 In their
model, mice were first immunized with goat anti-
mouse IgD antiserum. This induced the secretion of
IL-3 and IL-4 from T cells, and these cytokines in turn
promoted the production of large amounts of IgE and
IgG antibodies specific to goat IgG. The intravenous
injection of goat IgG induced systemic anaphylaxis,
which was inhibited by the treatment of mice with
anti-FcγR IIIII mAb before the allergen challenge.
Moreover, the anaphylaxis could be induced even in
mast cell-deficient or FcεRIα-deficient mice although
some decrease in the severity of anaphylaxis was ob-
served in the latter mice compared to wild-type mice.
The PAF antagonist completely inhibited this type of
anaphylaxis. These results demonstrated that the
allergen-induced anaphylaxis in this system is mast
cell-independent but depends on FcγR III and PAF.
Of note, intravenous injection of gadolinium chloride
before the allergen challenge almost completely abol-
ished the allergen-induced anaphylaxis.27 Gadolinium
chloride is known to inactivate or deplete macro-
phages. Therefore, it was concluded that macro-
phages play the major role in the IgG-mediated sys-
temic anaphylaxis through release of PAF (Fig.1 bot-
tom).27
It remains to be clarified what makes the difference
in the cell types responsible for the IgG-mediated
anaphylaxis between this model and our model. Be-
side the allergens and immunization protocols, the
mouse strains utilized in two studies were different.
We mainly performed the experiments using mouse
strains with the C57BL6 background as many
genetically-engineered mice have this genetic back-
ground.15 In contrast, Finkelman’s group mainly util-
ized mouse strains with the BALBc background.27 If
the difference is indeed attributed to the genetic
background, it is important to explore the molecular
basis of the difference. This might help understand-
ing the possible difference in the susceptibility to and
the severity of anaphylaxis among individual human
subjects with different genetic backgrounds.
POSSIBLE ROLES FOR BASOPHILS IN HUMAN
ANAPHYLAXIS
It remains uncertain whether the alternative anaphy-
laxis pathway utilizing IgG, PAF and basophils or
macrophage is operative in humans. The studies in
the mouse models revealed that higher amounts of
antigens and antibodies are needed to induce the
IgG-mediated anaphylaxis compared to the IgE-
mediated one.15,30 If this is also the case in humans, it
would be rare to find the case of the IgG-mediated
anaphylaxis in patients with allergy against foods or
insect venoms. However, in certain situations such as
medication, relatively large amounts of antigens in-
cluding therapeutic antibodies are introduced into
the body, which might trigger the production of large
amounts of IgG against such antigens. Several case
studies reported that anaphylaxis occurred in the ap-
parent absence of detectable allergen-specific IgE in
serum or in the absence of increase in serum tryptase
levels as an indication of mast cell degranulation.31,32
Allergen-specific IgG antibodies instead of IgE were
detected in individuals who manifested systemic ana-
phylaxis against medical reagents such as protamine,
dextran, and recombinant IgG including anti-
TNFα.31,33-35 Human basophils have been shown to
release PAF in response to various stimuli,36 al-
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Fig. 3 The development of tri-phasic ear sweling in the IgE transgenic mice af-
ter the alergen chalenge. TNP-specific IgE transgenic mice were chalenged 
with subcutaneous injection of TNP-OVA. The time course of ear thickness is 
shown. The immediate-phase ear sweling was observed within 1 hr after the al-
lergen chalenge, folowed by the late-phase ear sweling 6―10 hr later. The 
delayed-onset ear sweling started on day 2, and peaked on day 4.
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though it remains to be determined whether allergen-
IgG immune complexes stimulate human basophils
to release PAF. It has been recently reported that se-
rum PAF levels are correlated with the severity of
anaphylaxis in patients.37 Therefore, it would be
worthwhile to reassess the possible involvement of
basophils and PAF in human cases of anaphylaxis,
particularly in those with high levels of serum IgG
but not IgE specific to a relevant allergen. The pre-
treatment of high-risk patients with PAF antagonists
together with anti-histamine before medications
might be beneficial for the prevention of anaphylaxis.
THE ROLE FOR BASOPHILS IN CHRONIC
ALLERGIC INFLAMMATION
JONES-MOTE HYPERSENSITIVITY AND CUTA-
NEOUS BASOPHIL HYPERSENSITIVITY
In 1970s, the cutaneous delayed-type hypersensitivity
reaction containing large basophil infiltrate was ex-
tensively studies.38 It was termed Jones-Mote hyper-
sensitivity (JMH) in humans39 or cutaneous basophil
hypersensitivity (CBH) in guinea pigs.40 CBH is dis-
tinct from the classical delayed-type (tuberculin test-
type) hypersensitivity in several aspects.38 In general,
CBH is elicited by immunization of proteins in incom-
plete Freund’s adjuvant (without mycobacterial com-
ponents) whereas the immunization using complete
Freund’s adjuvant (with mycobacterial components)
is usually needed to elicit the classical hypersensitiv-
ity. CBH is characterized by erythema and slight
thickening, peaks at 18―24 hr after the antigen chal-
lenge and fades by 48 hr. The classical delayed-type
hypersensitivity is characterized by erythema and in-
duration, reaches its maximal intensity within 24 to
30 hr, and remains indurated after 48 to 72 hr. Baso-
phils constitute as much as 80% of the dermal infil-
trates in guinea pig CBH whereas basophils are
poorly recruited into the skin lesions of the classical
hypersensitivity. It was originally reported that CBH
could be transferred passively with lymphocytes
(most likely T cells) from sensitized animals to naïve
animals, but not with the serum from sensitized ani-
mals, as observed in the classical delayed-type hyper-
sensitivity.41 Later studies demonstrated that IgG1 or
IgE from sensitized guinea pigs could also transfer
CBH.42,43 The studies on JMH and CBH peaked in
1970s and promptly faded out thereafter, as judged
from the numbers of publication regarding these re-
actions. This may stem from the fact that mice, a pow-
erful experimental model animal, hardly developed
CBH. At that time, this failure was thought to be ow-
ing to the lack of circulating basophils in mice. Thus,
the pathogenesis and molecular mechanism underly-
ing the JMH and CBH reactions remain to be clari-
fied.
ALLERGEN-SPECIFIC, IgE-MEDIATED CHRONIC
ALLERGIC INFLAMMATION
We have established a panel of IgE transgenic mice
that constitutively produce monoclonal IgE specific to
allergens such as OVA and the hapten 2, 4, 6-
trinitrophenol (TNP).44,45 Intravenous injection of the
allergen elicited the typical systemic anaphylaxis in
these mice,44 as expected. Subcutaneous injection of
Mukai K et al.
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Fig. 4 A proposed mode of IgE-mediated chronic alergic inflammation. 
When IgE-bearing basophils are recruited into the peripheral tissue and en-
counter the relevant alergens, basophils are activated to secrete soluble fac-
tors including cytokines. These factors act on surounding tissue-resident 
cels to induce the production of chemokines that in turn recruit large num-
bers of proinflammatory cels such as eosinophils and neutrophils, resulting 
in chronic alergic inflammation.
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TNP-conjugated OVA (TNP-OVA) induced the typical
immediate-type skin reactions, that is, the early-phase
ear swelling within 1 hr after the allergen challenge
followed by the late-phase ear swelling 6―10 hr later
(Fig.3). Importantly, after the late-phase swelling sub-
sided, the ear swelling started again on day 2 and
peaked on day 4 (Fig.3).45 This delayed-onset swel-
ling was much more intense than the first and second
ones, and the ear thickness became twice the basal
level or that of ears challenged with control OVA.
Histopathological examination revealed the massive
infiltration of eosinophils in the skin lesions as well as
hyperplastic epidermis with hyperkeratosis. This IgE-
mediated chronic allergic inflammation (IgE-CAI)
was elicited not only in the TNP-specific IgE trans-
genic mice but also in mice that had been passively
sensitized with exogenous TNP-specific IgE one day
before the challenge with TNP-OVA.11 These obser-
vations indicated that IgE was involved in both imme-
diate and chronic allergic reactions in the skin.
The delayed-onset ear swelling with inflammation
was ameliorated by the treatment of mice with im-
munosuppressants such as cyclosporine A and ster-
oids, suggested that T cells might be involved in the
development of IgE-CAI.45 However, T cell-deficient
mice could develop the allergic inflammation with
massive eosinophil infiltration to the same extent as
did wild-type mice. Furthermore, mast cell-deficient
mice also elicited IgE-CAI even though they failed to
develop the early- and late-phase ear swelling. Thus,
T cells and mast cells were dispensable for the devel-
opment of IgE-CAI.11. The absence of IgE-CAI in
FcεRI-deficient mice suggested that FcεRI-expressing
cells other than mast cells might be responsible for
the development of IgE-CAI.
BASOPHIL FUNCTIONS AS AN INITIATOR
RATHER THAN AN EFFECTOR IN IgE-
MEDIATED CHRONIC ALLERGIC INFLAMMA-
TION
The cell transfer of various types of cells in the bone
marrow from wild-type mice to FcεRI-deficient mice
demonstrated that IgE-CAI could be reconstituted in
FcεRI-deficient mice only when CD49b (DX5)-
positive cells were transferred.11 Approximately 20%
of the CD49b+ cells expressed FcεRI on their cell sur-
faces, and possessed lobulated nuclei. These pheno-
types and the characterization of secretory granules
by the electron microscopic examination defined the
CD49b+FcεRI+ cells as basophils.11 Taken together, it
was concluded that basophils were responsible for
the development of IgE-CAI. Flow cytometric analysis
demonstrated that basophils were indeed recruited
into the skin lesions. However, they accounted for
only ～2% of the infiltrates whereas eosinophils and
neutrophils were abundant, raising the big question
how such a small number of basophils could induce
the allergic inflammation.
The treatment of mice with the basophil-depleting
mAb Ba103 before the allergen challenge prevented
the development of IgE-CAI,12 confirming the critical
role for basophils in IgE-CAI. The administration of
Ba103 during the progress of the dermatitis showed a
therapeutic effect, resulting in suppression of ear
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swelling and inflammation in the skin lesions.12 Of
note, the numbers of eosinophils and neutrophils in-
filtrated in the skin lesions were drastically reduced
by the treatment, concomitantly with the elimination
of basophils from the inflammation sites. This cannot
be expected if basophils, eosinophils and neutrophils
were independently recruited to the skin lesions.
These results strongly suggested that basophils
might function as initiators rather than effectors of
the allergic inflammation, and recruit other proinflam-
matory cells such as eosinophils and neutrophils.12
Our preliminary experiments support the following
scenario (Fig.4). When IgE-bound basophils are re-
cruited to the peripheral tissue such as skin in re-
sponse to the relevant allergens (through an unidenti-
fied mechanism, most likely via chemokines), and en-
counter the allergens, they are activated through the
FcεRI-mediated signal to secrete soluble factors in-
cluding cytokines and proteases. These factors in
turn act on tissue-resident cells such as fibroblasts to
secrete a variety of chemokines that recruit proin-
flammatory cells including eosinophils and neutro-
phils, resulting in the chronic allergic inflammation.
POSSIBLE ROLES FOR BASOPHILS IN
CHRONIC ALLERGIC INFLAMMATION IN HU-
MAN
It remains to be determined whether the IgE-CAI-
type mechanism is also operative in human allergic
disorders. However, there is circumstantial evidence
for this. A number of cohort studies indicated the cor-
relation between the disease severity and serum IgE
levels in patients with atopic dermatitis or asthma,
particularly in younger people.46,47 Recent clinical tri-
als with humanized anti-IgE antibody (omalizumab)
demonstrated that the decrease in serum IgE
achieved by the treatment is correlated with improve-
ment of the severity of symptoms in some poorly con-
trolled asthma patients.48-50 These results suggest the
possible involvement of IgE in the pathogenesis of
chronic allergic disorders. The infiltration of baso-
phils has often been observed in the affected tissues
in chronic allergic disorders including asthma and
atopic dermatitis.51-56 However, the numbers of infil-
trated basophils were usually much fewer than those
of eosinophils and neutrophils, and therefore the sig-
nificance of basophil infiltration in the pathogenesis
remains uncertain. Given our observation that baso-
phils played a critical role in IgE-CAI in mice even
though they accounted for only ～2% of infiltrates, it
would be reasonable to assume that basophils con-
tribute to the initiation, prolongation or deterioration
of chronic allergic inflammation in some allergic pa-
tients.
CONCLUSION AND PERSPECTIVE
Recent advances in the basophil research have cast a
new light on the in vivo roles of basophils, that are
distinct from those played by mast cells.11-15 Baso-
phils are no longer regarded as redundant ‘circulat-
ing mast cells’. Basophils are one of the major players
in IgG-mediated anaphylaxis,15 and function as initia-
tors rather than effectors in IgE-mediated chronic al-
lergic inflammation,11 even though they account for
less than 1% of leukocytes in the body. The treatment
with cyclosporine A or steroids almost completely
suppressed the IgE-mediated chronic allergic inflam-
mation even in the absence of T cells,11,45 suggesting
that these immunosuppressants act on basophils be-
sides T cells.57-59 These findings make basophils and
their products promising therapeutic targets for aller-
gic disorders, even though it remains to be clarified
whether those roles for basophils identified in mice
are relevant to human counterparts. It is important to
understand the in vivo roles for basophils not only
under pathological conditions but also under physi-
ological conditions in order to develop the therapeu-
tic strategy targeting basophils.
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